Brought to you by 
J&J gets rights to MGI Pharma's Dacogen for MDS
11 Oct 2012
Executive Summary
Johnson & Johnson's Janssen-Cilag companies have been granted exclusive worldwide (excluding North America) development and marketing rights to MGI Pharma's Dacogen (decitabine). The methylase inhibitor is injected into patients with myelodysplastic syndromes (MDS; bone marrow disorders).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com